Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,122,249
  • Shares Outstanding, K 102,676
  • Annual Sales, $ 131,160 K
  • Annual Income, $ -95,500 K
  • EBIT $ -166 M
  • EBITDA $ -164 M
  • 60-Month Beta -1.26
  • Price/Sales 7.80
  • Price/Cash Flow N/A
  • Price/Book 2.73

Options Overview Details

View History
  • Implied Volatility 81.72% (+2.10%)
  • Historical Volatility 76.51%
  • IV Percentile 9%
  • IV Rank 8.75%
  • IV High 613.84% on 10/23/25
  • IV Low 30.71% on 09/04/25
  • Expected Move (DTE 22) 0.47 (4.39%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 2,085
  • Volume Avg (30-Day) 1,412
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 46,450
  • Open Int (30-Day) 52,795
  • Expected Range 10.18 to 11.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.15
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.18
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.30 +3.40%
on 02/05/26
12.50 -14.80%
on 01/27/26
-1.38 (-11.47%)
since 01/26/26
3-Month
7.90 +34.81%
on 12/08/25
13.20 -19.32%
on 01/21/26
+1.24 (+13.18%)
since 11/26/25
52-Week
5.64 +89.00%
on 08/06/25
13.20 -19.32%
on 01/21/26
+0.78 (+7.90%)
since 02/26/25

Most Recent Stories

More News
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded...

DAWN : 10.65 (-2.56%)
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 10.65 (-2.56%)
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate...

DAWN : 10.65 (-2.56%)
Day One Completes Acquisition of Mersana Therapeutics

BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies...

MRSN : 29.08 (+0.14%)
DAWN : 10.65 (-2.56%)
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 10.65 (-2.56%)
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off...

DAWN : 10.65 (-2.56%)
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 10.65 (-2.56%)
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid...

DAWN : 10.65 (-2.56%)
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval...

DAWN : 10.65 (-2.56%)
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million ...

DAWN : 10.65 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 11.51
2nd Resistance Point 11.21
1st Resistance Point 10.93
Last Price 10.65
1st Support Level 10.35
2nd Support Level 10.05
3rd Support Level 9.77

See More

52-Week High 13.20
Last Price 10.65
Fibonacci 61.8% 10.31
Fibonacci 50% 9.42
Fibonacci 38.2% 8.52
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar